Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Sciences Ireland Unlimited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CinFina Pharma In-Licenses Obesity Portfolio","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma & Perceptive Advisors","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinRx Pharma Announces First Participant Dosed in CinDome\u2019s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinRx Pharma Announces First Participant Dosed in CinDome\u2019s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by CinRx Pharma

    Menu

    CinRx Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CinRx Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity

              Details:

              CIN-110 is a potent and highly selective large molecule peptide and a PYY3-36 analog, which is currently under development for the treatment of Obesity.

              Lead Product(s): CIN-110

              Therapeutic Area: Nutrition and Weight Loss Product Name: CIN-110

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CinRx Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

              Details:

              The net proceeds will be used to develop CinDome Pharma’s Phase 2 envision3D study of CIN-102 (deudomperidone), a new chemical entity based upon deuteration and novel formulation of domperidone in patients with diabetic gastroparesis.

              Lead Product(s): Deudomperidone

              Therapeutic Area: Gastroenterology Product Name: CIN-102

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: CinRx Pharma & Perceptive Advisors

              Deal Size: $19.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement April 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CinRx Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

              Details:

              CIN-102 (deudomperidone) is a new chemical entity based upon deuteration and novel formulation of domperidone (DA2-receptor antagonist), a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States.

              Lead Product(s): Deudomperidone

              Therapeutic Area: Gastroenterology Product Name: CIN-102

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CinRx Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CinFina Pharma In-Licenses Obesity Portfolio

              Details:

              Under the agreement CinFina will be responsible for development, manufacturing and commercialization of CIN-109, with a multiple ascending dose Phase 1 clinical study, and following dose selection, will commence a Phase 2 study in overweight and obese adults in the US.

              Lead Product(s): CIN-109

              Therapeutic Area: Nutrition and Weight Loss Product Name: CIN-109

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Janssen Sciences Ireland Unlimited

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY